Kanamycin Sulfate

CHEMBL1446 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
582.6 g/mol
LogP
Phase
4

The sulfate salt form of kanamycin, an aminoglycoside antibiotic used to treat tuberculosis and other serious bacterial infections. It shares the same mechanism as the parent compound but in a salt form more suitable for pharmaceutical preparation.

Molekularmasse

582,6000 g/mol

TPSA

366,00 Ų

Therapeutische Bereiche

Wirkmechanismus

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O.O=S(=O)(O)O

InChI

InChI=1S/C18H36N4O11.H2O4S/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17;1-5(2,3)4/h4-18,23-29H,1-3,19-22H2;(H2,1,2,3,4)/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-;/m1./s1

Molecular Formula

C18H38N4O15S

HBD / HBA

13 / 19

Rotierbare Bindungen

6

Schwere Atome

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The sulfate salt form of kanamycin, an aminoglycoside antibiotic used to treat tuberculosis and other serious bacterial infections. It shares the same mechanism as the parent compound but in a salt form more suitable for pharmaceutical preparation.

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Yes, Kanamycin Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1446. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441374. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.